TUV

vamorolone

Created:	2020-04-01
Last modified:	2026-10-14

Find Related PDB Entry
1 entries where TUV is found as a standalone ligand

Find related ligands: Help
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	54
Chiral Atom Count	6
Bond Count	57
Aromatic Bond Count	0

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	vamorolone
Synonyms	(8~{S},10~{S},13~{S},14~{S},16~{R},17~{R})-10,13,16-trimethyl-17-oxidanyl-17-(2-oxidanylethanoyl)-7,8,12,14,15,16-hexahydro-6~{H}-cyclopenta[a]phenanthren-3-one
Systematic Name (OpenEye OEToolkits)	(8~{S},10~{S},13~{S},14~{S},16~{R},17~{R})-10,13,16-trimethyl-17-oxidanyl-17-(2-oxidanylethanoyl)-7,8,12,14,15,16-hexahydro-6~{H}-cyclopenta[a]phenanthren-3-one
Formula	C₂₂ H₂₈ O₄
Molecular Weight	356.455
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	14.52	OCC(=O)C1(O)C(C)CC2C3CCC4=CC(=O)C=CC4(C)C3=CCC21C
SMILES	CACTVS	3.385	C[CH]1C[CH]2[CH]3CCC4=CC(=O)C=C[C]4(C)C3=CC[C]2(C)[C]1(O)C(=O)CO
SMILES	OpenEye OEToolkits	3.1.0.0	CC1CC2C3CCC4=CC(=O)C=CC4(C3=CCC2(C1(C(=O)CO)O)C)C
Canonical SMILES	CACTVS	3.385	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO
Canonical SMILES	OpenEye OEToolkits	3.1.0.0	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@]1(C(=O)CO)O)C)C
InChI	InChI	1.06	InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1
InChIKey	InChI	1.06	ZYTXTXAMMDTYDQ-DGEXFFLYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB15114
Name	Vamorolone
Groups	investigational approved
Description	Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder characterized by the insidious regression of neuromuscular function and the most common form of muscular dystrophy in the United States.[L48676] Corticosteroid therapy is the current standard of care for DMD despite relatively high rates of adverse effects.[L48676] Vamorolone is positioned as having a more tolerable adverse effect profile than other corticosteroids owing to its unique receptor binding profile,[A261976] thus providing an additional treatment option in patients for whom corticosteroid adverse effects are intolerable or otherwise unacceptable.[L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505]
Synonyms	Vamorolone
Brand Names	Agamree
Indication	Vamorolone is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients ≥2 years of age in the US[L48671] and in patients ≥4 years of age in the EU.[L49500]
Categories	Adrenal Cortex Hormones Anti-Inflammatory Agents Corticosteroids Corticosteroids for Systemic Use Corticosteroids for Systemic Use, Plain Cytochrome P-450 CYP2C8 Substrates Cytochrome P-450 CYP3A Inducers Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Inducers Cytochrome P-450 CYP3A4 Inducers (strength unknown) Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A5 Substrates Cytochrome P-450 Enzyme Inducers Cytochrome P-450 Substrates Fused-Ring Compounds Glucocorticoids Pregnadienes Pregnanes Steroids Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins UGT1A3 substrates UGT2B17 substrates UGT2B7 substrates
ATC-Code	H02AB18
CAS number	13209-41-1

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

Name	Target Sequence	Pharmacological Action	Actions
Glucocorticoid receptor	MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAV...	unknown	agonist
Mineralocorticoid receptor	METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSC...	unknown	antagonist
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate,inducer
Cytochrome P450 3A5	MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...	unknown	substrate
Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...	unknown	substrate
UDP-glucuronosyltransferase 1A3	MATGLQVPLPWLATGLLLLLSVQPWAESGKVLVVPIDGSHWLSMREVLRE...	unknown	substrate
UDP-glucuronosyltransferase 2B7	MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRG...	unknown	substrate
UDP-glucuronosyltransferase 2B17	MSLKWMSVFLLMQLSCYFSSGSCGKVLVWPTEYSHWINMKTILEELVQRG...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682